These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 32499214

  • 1. Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA.
    Ziemssen T, Hoffmann O, Klotz L, Schreiber H, Weber MS, Rauser B.
    JMIR Res Protoc; 2020 Jul 24; 9(7):e19598. PubMed ID: 32499214
    [Abstract] [Full Text] [Related]

  • 2. Siponimod: A Review in Secondary Progressive Multiple Sclerosis.
    Scott LJ.
    CNS Drugs; 2020 Nov 24; 34(11):1191-1200. PubMed ID: 33108633
    [Abstract] [Full Text] [Related]

  • 3. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
    Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F, EXPAND Clinical Investigators.
    Lancet; 2018 Mar 31; 391(10127):1263-1273. PubMed ID: 29576505
    [Abstract] [Full Text] [Related]

  • 4. Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence.
    Sabsabi S, Mikhael E, Jalkh G, Macaron G, Rensel M.
    Patient Prefer Adherence; 2022 Mar 31; 16():1307-1319. PubMed ID: 35637684
    [Abstract] [Full Text] [Related]

  • 5. Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study.
    Hua LH, Bar-Or A, Cohan SL, Lublin FD, Coyle PK, Cree BA, Meng X, Su W, Cox GM, Fox RJ.
    Mult Scler Relat Disord; 2023 Jul 31; 75():104766. PubMed ID: 37245350
    [Abstract] [Full Text] [Related]

  • 6. Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis.
    Regner-Nelke L, Pawlitzki M, Willison A, Rolfes L, Oezalp SH, Nelke C, Kölsche T, Korsen M, Grothe M, Groppa S, Luessi F, Engel S, Nelles G, Bonmann E, Roick H, Friedrich A, Knorn P, Landefeld H, Biro Z, Ernst M, Bayas A, Menacher M, Akgün K, Kleinschnitz C, Ruck T, Ziemssen T, Pul R, Meuth SG.
    Neurol Res Pract; 2022 Nov 07; 4(1):55. PubMed ID: 36336685
    [Abstract] [Full Text] [Related]

  • 7. Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
    Gold R, Piani-Meier D, Kappos L, Bar-Or A, Vermersch P, Giovannoni G, Fox RJ, Arnold DL, Benedict RHB, Penner IK, Rouyrre N, Kilaru A, Karlsson G, Ritter S, Dahlke F, Hach T, Cree BAC.
    J Neurol; 2022 Sep 07; 269(9):5093-5104. PubMed ID: 35639197
    [Abstract] [Full Text] [Related]

  • 8. Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK.
    Montgomery S, Woodhouse F, Vudumula U, Gudala K, Duddy M, Kroes M.
    J Med Econ; 2022 Sep 07; 25(1):669-678. PubMed ID: 35575251
    [Abstract] [Full Text] [Related]

  • 9. Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
    Cree BA, Arnold DL, Fox RJ, Gold R, Vermersch P, Benedict RH, Bar-Or A, Piani-Meier D, Rouyrre N, Ritter S, Kilaru A, Karlsson G, Giovannoni G, Kappos L.
    Mult Scler; 2022 Sep 07; 28(10):1591-1605. PubMed ID: 35380078
    [Abstract] [Full Text] [Related]

  • 10. OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany.
    Ziemssen T, Richter S, Mäurer M, Buttmann M, Kreusel B, Poehler AM, Lampl M, Linker RA.
    Front Neurol; 2022 Sep 07; 13():913616. PubMed ID: 35832177
    [Abstract] [Full Text] [Related]

  • 11. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ, Figgitt DP.
    CNS Drugs; 2004 Sep 07; 18(6):379-96. PubMed ID: 15089110
    [Abstract] [Full Text] [Related]

  • 12. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.
    Boyko A, Therapontos C, Horakova D, Szilasiová J, Kalniņa J, Kolontareva J, Gross-Paju K, Selmaj K, Sereike I, Milo R, Gabelić T, Rot U.
    Mult Scler Relat Disord; 2021 May 07; 50():102778. PubMed ID: 33592384
    [Abstract] [Full Text] [Related]

  • 13. Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland.
    Schur N, Gudala K, Vudumula U, Vadapalle S, Bhadhuri A, Casanova A, Adlard N, Schwenkglenks M.
    Pharmacoeconomics; 2021 May 07; 39(5):563-577. PubMed ID: 33791945
    [Abstract] [Full Text] [Related]

  • 14.
    ; 2020 09 07. PubMed ID: 33497149
    [Abstract] [Full Text] [Related]

  • 15. Siponimod for the treatment of secondary progressive multiple sclerosis.
    Dumitrescu L, Constantinescu CS, Tanasescu R.
    Expert Opin Pharmacother; 2019 Feb 07; 20(2):143-150. PubMed ID: 30517042
    [Abstract] [Full Text] [Related]

  • 16. [Disease-modifying treatment of secondary progressive multiple sclerosis].
    Hoffmann O, Gold R.
    Nervenarzt; 2021 Oct 07; 92(10):1052-1060. PubMed ID: 33656569
    [Abstract] [Full Text] [Related]

  • 17. Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.
    Benedict RHB, Tomic D, Cree BA, Fox R, Giovannoni G, Bar-Or A, Gold R, Vermersch P, Pohlmann H, Wright I, Karlsson G, Dahlke F, Wolf C, Kappos L.
    Neurology; 2021 Jan 19; 96(3):e376-e386. PubMed ID: 33328324
    [Abstract] [Full Text] [Related]

  • 18. [Siponimod: a new view at the therapy of secondary progressive multiple sclerosis].
    Krasnov VS, Kolontareva YM.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021 Jan 19; 121(7):124-129. PubMed ID: 34460168
    [Abstract] [Full Text] [Related]

  • 19. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
    Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS, Stüve O, Rieckmann P, Montalban X, Ziemssen T, Auberson LZ, Pohlmann H, Mercier F, Dahlke F, Wallström E.
    Lancet Neurol; 2013 Aug 19; 12(8):756-67. PubMed ID: 23764350
    [Abstract] [Full Text] [Related]

  • 20. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study.
    Kappos L, Li DK, Stüve O, Hartung HP, Freedman MS, Hemmer B, Rieckmann P, Montalban X, Ziemssen T, Hunter B, Arnould S, Wallström E, Selmaj K.
    JAMA Neurol; 2016 Sep 01; 73(9):1089-98. PubMed ID: 27380540
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.